CBUS - Cibus, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

CBUS

CIBUS, INC.

NASDAQ

$1.68

▼ DOWN 1.75% (-0.03)

KEY STATISTICS

Market Cap$128.90 M

52w High$4.19

52w Low$1.09

Dividend Yield—

Frequency—

P/E-1.14

Volume231.40K

Shares Out.76.33M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Craig Wichner

COMPENSATION 2026

Salary$630,579

Stock Awards$276,100

Incentive Plan Pay$0

All Other Comp.$0

Total$1,364,345

ABOUT

SECTOR

Healthcare

WENT PUBLIC

July 20, 2017

METHOD OF GOING PUBLIC

N/A

FULL TIME EMPLOYEES

118

PRICE TARGET

Target High$12.50

Target Low$10.50

Target Median$11.50

Target Consensus$11.50

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.$1.30M

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2023-06-01	Reverse	1:5
2023-04-25	Reverse	1:10

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

23.94%

HOLDERS

TOP 8 OF 86 · RANKED BY POSITION SIZE

Fmr LLC

11.4M sh

$22.62M

Davidson Kempner Capital Management LP

Vantage Consulting Group Inc

Weiss Asset Management LP

888.1K sh

$1.76M

United Capital Financial Advisers, LLC

576.0K sh

$1.14M

Geode Capital Management, LLC

482.9K sh

$956.47K

PRICE

$1.68 ▼ DOWN 1.75% (−$0.03)

OVERLAYS

About Cibus, Inc.

https://www.cibus.com ↗

Cibus, Inc. is an agricultural tech company in San Diego that develops and licenses plant traits to boost yields, reduce chemical use, and enable sustainable ingredient replacements for seed companies.

INDUSTRY

Biotechnology

A PRODUCT CIBUS, INC. IS KNOWN FOR

Second-Generation Herbicide Tolerance (HT2) Trait in Canola

Cibus's gene-edited canola trait offers herbicide tolerance for improved weed management, with successful 2025 field trials and a "not regulated" USDA status paving the way for commercial launch.

COMPETITORS

COMPETITOR

Cibus in 2025

SENTIMENT: + POSITIVE

REGULATORY · THROUGHOUT 2025

Cibus Secures Key Regulatory Wins in 2025, Paving the Way for Commercialization of its Gene-Edited Crops

Throughout 2025, Cibus, Inc. achieved a series of critical regulatory milestones that significantly de-risked its path to commercialization. Key events included the completion of the FDA's review for its altered lignin alfalfa in June, the USDA's designation of its herbicide-tolerant canola trait (HT2) as not regulated, and a landmark decision by the EU to move forward with a new regulatory framework for gene-edited plants in December. These, along with positive determinations in Ecuador and California for its rice traits, collectively signaled growing global acceptance of Cibus's gene-editing technology, boosting investor confidence and media attention.

RESTRUCTURING · JUNE/JULY 2025 · IN PROGRESS

Cibus Restructures to Prioritize Commercialization of Rice Traits and Sustainable Ingredients, Targeting a $30M Annual Cash Burn Rate

Cibus initiated a strategic realignment to streamline its operations, concentrating on the commercial advancement of its weed management traits in rice and partner-funded sustainable ingredient programs. This strategic shift includes a reduction in force to align the company's cost structure with its more focused commercial priorities.